Cyclooxygenase-2 overexpression in ovarian endometriomas is associated with higher risk of recurrence

Other OA: closed CC0 ⤵ 29 in-corpus citations
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Ovarian endometriomas with higher cyclooxygenase-2 expression were associated with an increased risk of recurrence.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Cyclooxegenase-2 expression was evaluated by immunohistochemistry in endometrioma tissue samples taken from 109 patients, of whom 53 had recurrence by 30 months after surgery and 56 did not. Cyclooxegenase-2 overexpression, along with previous medical treatment of endometriosis and the presence of adhesion, is predictive of recurrence of ovarian endometrioma within 30 months after surgery, with a resultant sensitivity of 72.5% and a specificity of 72.4%, suggesting that there are intrinsic and identifiable biomarkers that confer recurrence risk.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Cyclooxygenase 2 Endometriosis Endometriosis Ovarian Diseases Ovarian Diseases Adult Adult Biomarkers Biomarkers Biomarkers Case-Control Studies Case-Control Studies Cyclooxygenase 2 Cyclooxygenase 2 Endometriosis Endometriosis Endometriosis Female Female Gene Expression Regulation, Enzymologic

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (28)

Cited by (28)

Source provenance

europepmc
last seen: 2026-10-15T06:08:49.021275+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:05:10.907216+00:00
unpaywall
last seen: 2026-08-12T06:43:03.944938+00:00
License: CC0 · commercial use OK